MedTrace Logo

Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt

NCT04773756 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2021-02-26

No results posted yet for this study

Summary

Sofosbuvir has been recently recommended as a possible antiviral for COVID-19, based on structural studies and multiple alignment analysis. By comparing the positive-stranded RNA genomes of HCV and SARS-CoV-2, it has been postulated that sofosbuvir might be an optimal nucleotide analogue to repurpose for COVID-19 treatment

Conditions

  • Covid19

Interventions

DRUG

Sofosbuvir 400 MG/ Daclatasvir 60mg

Giving these two drugs for treatment of COVID patients

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Amr Abd elmoety, PhD · Alexandria University, Faculty of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2020-11-30
Completion
2020-12-12
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04773756 on ClinicalTrials.gov